Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113

Benzinga · 4d ago
Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.